Skip to main content

Table 3 The clinical outcomes of UI-EWD in tumor bleeding

From: Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding

Variables Total enrolled patients
(n = 41)
UI-EWD monotherapy
(n = 23)
Success of Immediate hemostasis, n (%) 40 (97.5) 23 (100.0)
Cumulative re-bleeding, n (%) 9/40 (22.5) 6/23 (26.1)
At 7 day 3 (7.5) 1 (4.3)
At 28 days 9 (22.5) 6 (26.1)
At 180 days 9 (22.5) 6 (26.1)
Time to re-bleeding (day)§ 10 (1–23) 12 (7–22)
RBC transfusion (unit)§ 2 (0–6) 2 (0–6)
Hospital days§ 10 (3–48) 10 (5–45)
After failure of hemostasis, method for treatment, n (%)   
Embolization 1 (100.0) 0 (0.0)
Surgery 0 (0.0) 0 (0.0)
Conservative management 0 (0.0) 0 (0.0)
  1. RBC, red blood cell
  2. §, median (range)